ARGENT BIOPHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.415 AUD | 0.00% |
|
-3.49% | -12.63% |
Valuation
| Fiscal Period: Juni | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 79.39 | 63.1 | 31.51 | 85.5 | 43.65 | 16.75 |
| Enterprise Value (EV) 1 | 69.55 | 60.74 | 31.54 | 86.08 | 46.12 | 26.27 |
| P/E ratio | -9.01 x | -27.2 x | -1.43 x | -4.44 x | -2.02 x | -0.7 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 267 x | 96.1 x | 15.2 x | 28.9 x | 9.22 x | 4.95 x |
| EV / Revenue | 234 x | 92.6 x | 15.2 x | 29.1 x | 9.75 x | 7.75 x |
| EV / EBITDA | -10.3 x | -7.19 x | -2.88 x | -7.65 x | -2.99 x | -1.79 x |
| EV / FCF | -97.2 x | -6.2 x | -5.24 x | -6.95 x | -5.24 x | -4.73 x |
| FCF Yield | -1.03% | -16.1% | -19.1% | -14.4% | -19.1% | -21.1% |
| Price to Book | 5.7 x | 5.76 x | 10.1 x | 6.2 x | 7.48 x | -2.26 x |
| Nbr of stocks (in thousands) | 1,203 | 1,213 | 1,576 | 2,311 | 2,728 | 3,351 |
| Reference price 2 | 66.00 | 52.00 | 20.00 | 37.00 | 16.00 | 5.000 |
| Announcement Date | 9/2/18 | 8/28/19 | 9/30/20 | 9/30/21 | 10/2/22 | 9/29/23 |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Juni | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.2968 | 0.6562 | 2.079 | 2.963 | 4.732 | 3.388 |
| EBITDA 1 | -6.725 | -8.452 | -10.96 | -11.25 | -15.4 | -14.69 |
| EBIT 1 | -7.053 | -8.712 | -11.29 | -11.59 | -15.5 | -15.23 |
| Operating Margin | -2,376.25% | -1,327.51% | -542.8% | -391.22% | -327.54% | -449.72% |
| Earnings before Tax (EBT) 1 | -8.99 | -1.876 | -18.77 | -15.44 | -20.77 | -21.13 |
| Net income 1 | -8.246 | -2.309 | -19.36 | -15.87 | -20.35 | -20.82 |
| Net margin | -2,778.31% | -351.91% | -931.29% | -535.62% | -430% | -614.71% |
| EPS 2 | -7.327 | -1.910 | -14.03 | -8.343 | -7.929 | -7.100 |
| Free Cash Flow 1 | -0.7154 | -9.801 | -6.022 | -12.38 | -8.806 | -5.55 |
| FCF margin | -241.03% | -1,493.47% | -289.63% | -417.95% | -186.09% | -163.85% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 9/2/18 | 8/28/19 | 9/30/20 | 9/30/21 | 10/2/22 | 9/29/23 |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 0.03 | 0.58 | 2.47 | 9.51 |
| Net Cash position 1 | 9.84 | 2.35 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | -0.002358 x | -0.0519 x | -0.1601 x | -0.6475 x |
| Free Cash Flow 1 | -0.72 | -9.8 | -6.02 | -12.4 | -8.81 | -5.55 |
| ROE (net income / shareholders' equity) | -63.1% | -16.2% | -270% | -182% | -219% | 1,482% |
| ROA (Net income/ Total Assets) | -21.6% | -33% | -67.4% | -45% | -45.3% | -66.7% |
| Assets 1 | 38.18 | 6.996 | 28.72 | 35.23 | 44.94 | 31.21 |
| Book Value Per Share 2 | 11.60 | 9.030 | 1.970 | 5.960 | 2.140 | -2.210 |
| Cash Flow per Share 2 | 8.200 | 1.940 | 1.190 | 2.340 | 0.6900 | 0.0700 |
| Capex 1 | 0.46 | 0.38 | 0.96 | 3.33 | 2.69 | 0.19 |
| Capex / Sales | 154.79% | 57.46% | 46.27% | 112.29% | 56.91% | 5.6% |
| Announcement Date | 9/2/18 | 8/28/19 | 9/30/20 | 9/30/21 | 10/2/22 | 9/29/23 |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +37.08% | 5.92B | |
| -17.43% | 4.51B | |
| -9.46% | 3.15B | |
| +0.51% | 3.1B | |
| -3.53% | 2.42B | |
| +41.15% | 1.97B | |
| -5.15% | 1.68B | |
| +0.09% | 1.65B | |
| -10.38% | 1.53B |
- Stock Market
- Equities
- RGT Stock
- MXC Stock
- Financials Argent BioPharma Limited
